Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDHGM2)

• Drug Name: MAACKIAIN Drug Info
• Synonyms: Maackiain; (-)-Maackiain; Inermin; Inermine; 2035-15-6; L-Maackiain; CHEBI:99; UNII-TF360D25IJ; (6ar,12ar)-6a,12a-dihydro-6h-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-3-ol; TF360D25IJ; HUKSJTUUSUGIDC-ZBEGNZNMSA-N; 19908-48-6; 3-Hydroxy-8,9-methylenedioxypterocarpan; ST077155; (6aR,12aR)-3-hydroxy-8,9-methylenedioxypterocarpane; (6aR,12aR)-6a,12a-Dihydro-6H-[1,3]dioxolo[4',5':5,6]benzofuro[3,2-c]chromen-3-ol; Maackiaine; Trifolirhizin aglycone; (+/-)-Maackiain; AC1Q70VV; CHEMBL334918; AC1L3M84; (-)-(6aR,12aR)-maackiain

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 91510
  ChEBI ID: CHEBI:99
  CAS Number: CAS 2035-15-6
  TTD Drug ID: DMDHGM2
  VARIDT Drug ID: DR00929

Molecule-Related Drug Atlas

Drug(s) Targeting SLC5A2 messenger RNA (SLC5A2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexagliflozin	DMK56G0	Type 2 diabetes	5A11	Approved	[3]
ISIS-SGLT2	DMDKAIC	Type-2 diabetes	5A11	Phase 1	[4]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[1]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[1]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[5]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[5]
Kushenol N	DMY13UR	Discovery agent	N.A.	Investigative	[1]
Alstiphyllanine E	DMTNQ5E	Discovery agent	N.A.	Investigative	[5]
Burnamine-17-O-3',4',5'-trimethoxybenzoate	DMBO0WI	Discovery agent	N.A.	Investigative	[5]
Alstiphyllanine D	DM2FLDJ	Discovery agent	N.A.	Investigative	[5]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[6]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[6]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[6]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[7]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[2]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[8]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[9]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[10]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[11]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[12]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[13]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[14]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[15]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[16]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[17]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[18]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[19]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[20]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[21]

Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[23]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[24]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[25]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[26]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[27]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[7]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[17]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[28]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[29]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[14]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[30]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[17]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[16]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[7]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[31]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[17]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[32]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[16]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[17]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[14]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[33]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[16]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[34]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[7]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[17]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[8]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[17]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[33]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SLC5A2 messenger RNA (SLC5A2 mRNA)	TTF8JAT	SC5A2_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[2]

References

• [1] Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
• [2] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [5] Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
• [6] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [7] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [8] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [9] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [10] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [11] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [12] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [13] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [14] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [15] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [16] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [17] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [18] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [19] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [20] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [21] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [22] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [23] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [24] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [25] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [26] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [27] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [28] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [29] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
• [30] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [31] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [32] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [33] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [34] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.